SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NPSP NPS Pharmaceutical
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
363 40 0 NPSP
Emcee:  Jim Langdon Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
188>>SALT LAKE CITY, Feb. 10 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Ituck-2/10/2004
187<<If the cancer study against expectations should turn out positive it wouMiljenko Zuanic-11/20/2003
186Results do seem somewhat better than for Forteo. Not sure if it's enough to Biomaven-11/20/2003
185NPS Reports Positive PREOS Study Results 11/20/2003 6:03:00 AM SALT LAKE CITY, mopgcw-11/20/2003
184it does seem odd -- circle the wagons type stuff -- usually they seem to just ismopgcw-11/20/2003
183No, not necessarily. The results are very eagerly awaited, so a CC is not out ofIcebrg-11/20/2003
182Does this sound like trouble???? Press Release Source: NPS Pharmaceuticals, IncMiljenko Zuanic-11/19/2003
181GS rates it in-line/neutral, whatever that means. I am not sure GS provides primopgcw-11/17/2003
180and here's the NPSP end of the ML take: Phase III data suggests that Cinacatom pope-11/17/2003
179Here's what ML has to say <i>Amgen (AMGN) - Raise 04 and 05 estimatestom pope-11/17/2003
178Thanks, mopgcw, but that is really quite funny. Although I understand every wordtom pope-11/17/2003
177GS Note: NPS Pharmaceuticals, Inc. EPS (FY Dec) 2003E ($3.41), 2004E ($3.02) Inmopgcw-11/17/2003
176GS Note: NPS Pharmaceuticals, Inc. EPS (FY Dec) 2003E ($3.41), 2004E ($3.02) In-mopgcw-11/10/2003
175From GS: NPS Pharmaceuticals, Inc. EPS (FY Dec) 2003E ($3.41), 2004E ($3.02) Inmopgcw-11/10/2003
174Just in case the royaly rate and peak sales projections for Cinacalcet have not tuck-10/16/2003
173NPS Pharmaceuticals Announces Completion Of Top Study Dosing, Launch Of CrohnSemiBull-10/8/2003
172NPS Pharmaceuticals Announces Completion of Top Study Dosing, Launch of CrohnIcebrg-10/7/2003
171Thanks. Speeding up the rehabilitation of bone fractures would be a very interIcebrg-9/30/2003
170Since you're probably not in tune to US sports, I'll translate. From ESPrkrw-9/29/2003
169NPS shares drop on bone-drug data, editorial Monday September 22, 4:44 pm ET By Icebrg-9/22/2003
168NPS Comments on Interim Results of PaTH Study Data Saturday September 20, 1:30 pIcebrg-9/20/2003
167Preos and Forteo. The articles and the editorial are actually available at the Icebrg-9/20/2003
166Osteoporosis drugs no better in combination-study Saturday September 20, 12:27 pIcebrg-9/20/2003
165Investor Alert NPS Pharmaceuticals, Inc. has posted a new event to its investorIcebrg-9/19/2003
164Lilly drug for severe osteoporosis wins respect Friday September 19, 1:05 pm ET Icebrg-9/19/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News